Literature DB >> 7850751

Mutational activation of ras genes is absent in pediatric osteosarcoma.

F Antillón-Klüssmann1, M García-Delgado, I Villa-Elízaga, L Sierrasesúmaga.   

Abstract

Activation of ras oncogenes is found in human cancers; overall it is observed in 15% of all neoplasms. The purpose of this study was to assess the extent of involvement of ras oncogenes in osteosarcoma. Tumor samples from a series of 49 pediatric patients diagnosed with osteosarcoma and treated at our institution were evaluated. Paraffin-embedded tumor samples from diagnostic biopsies, from tumor en bloc resection tissue after neoadjuvant chemotherapy, and samples from metastases were examined in search of point mutations in H, K, and N-ras genes at codons 12 and 61 by means of polymerase chain reaction (PCR), slot-blotting, and radioactive labeled specific DNA probes. A total of 92 archival samples were studied. No point mutations activating these genes were found. These findings suggest that the activation by point mutations at codons 12 and 61 of the H, K, and N-ras genes does not play a role in the pathogenesis of human osteosarcoma. Since no point mutations in codons 12 and 61 were detected, it was not possible to establish any correlation between the ras genes and clinical or histologic findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850751     DOI: 10.1016/0165-4608(94)00115-r

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].

Authors:  Mandy Geryk-Hall; Yanwen Yang; Dennis P M Hughes
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

2.  Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential.

Authors:  Nan Li; Rui Yang; Wendong Zhang; Howard Dorfman; Pulivarthi Rao; Richard Gorlick
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.